October 1st 2024
During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
September 18th 2024
September 16th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Brentuximab Combo Demonstrates Positive Efficacy in Advanced Hodgkin Lymphoma
December 11th 2023Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine appears to be well tolerated in patients with advanced stage classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial.
Read More
Dose-Escalation/Expansion Trial Evaluates NX-1607 Across Cancer Settings
December 11th 2023An ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.
Read More
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
December 10th 2023In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response
December 10th 2023Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.
Read More
Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL
December 10th 2023The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.
Read More
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Read More
Zanubrutinib Induces Sustained PFS Benefit in Relapsed/Refractory CLL/SLL
December 10th 2023According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL
December 10th 2023Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
Read More
FDA’s ODAC Confronts Issues With Accelerated Approval Program
November 16th 2023The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.
Read More
Pembrolizumab After ASCT is Feasible in Peripheral T-Cell Lymphoma
November 7th 2023In an interview, Mwanasha Merrill discussed the implication of findings from a phase 2 trial of pembrolizumab after autologous stem cell transplantation for the treatment of patients with peripheral T-cell lymphoma.
Read More
Preliminary Clinical Activity Observed With Paxalisib in R/R PCNSL
November 2nd 2023With over half of the patients enrolled in the phase 2 trial evaluating paxalisib in relapsed/refractory primary central nervous system lymphoma, some partial responses and stable disease have already been seen.
Read More
Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL
October 25th 2023At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab and lenalidomide fits in.
Read More
First-line Treatment of VR-CAP Regimen Shows Efficacy in Marginal Zone Lymphoma
October 23rd 2023In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.
Read More